Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...